TGF-β in diabetic kidney disease: Role of novel signaling pathways

Cytokine and Growth Factor Reviews

Volumn 11, Issue 1-2, 2000, Pages 115-123

  Sharma, Kumar ^a   McGowan, Tracy A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 4; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; CALCIUM CHANNEL; CELL PROLIFERATION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; EXTRACELLULAR MATRIX; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY; KIDNEY FAILURE; MESANGIUM; METABOLISM; MOUSE; NONHUMAN; RAT; REVIEW; SIGNAL TRANSDUCTION; VASCULAR DISEASE; VASCULARIZATION;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; EXTRACELLULAR MATRIX; GLOMERULAR MESANGIUM; HUMANS; KIDNEY; RATS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

ANIMALIA; GLOMERULUS;

EID: 0034106182     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6101(99)00035-0     Document Type: Review

References (64)

1. Report U.S.R.D.S.A. Incidence and Prevalence of ESRD. Am. J. Kidney D. 34S1:1999;S40-S50.
2. The Diabetes Control, Complications Trial Research Group. The effects of intensive insulin treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329:1993;977-986.
3. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS. BMJ. 317:1998;703-713.
4. Lewis E.J., Hunsicker L.G., Bain R.P., Rohde R.D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N. Engl. J. Med. 329:1993;1456-1462.
5. Ritz E., Orth S. Nephropathy in patients with type 2 diabetes mellitus. New Engl. J. Med. 341:1999;1127-1133.
6. Fioretto P., Steffes M., Sutherland D., Mauer M. Sequential renal biopsies in insulin-dependent diabetic patients: Structural factors associated with clinical progression. Kidney International. 48:1995;1929-1935.
7. Sharma K., Ziyadeh F.N. Hyperglycemia and diabetic kidney disease: the case for transforming growth factor-β as a key mediator. Diabetes. 44:1995;1139-1146.
8. O'Bryan G., Hostetter T. The renal hemodynamic basis of diabetic nephropathy. Sem. Nephrol. 17:1997;93-100.
9. Mauer S.M., Ellis E.N., Bilous R.W., Steffes M.W. The pathology of diabetic nephropathy. Complications of diabetes mellitus. 1989;95-101.
10. Steffes M.W., Osterby R., Chavers B., Mauer S.M. Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. Diabetes. 38:1989;1077-1081.
11. Strutz F., Muller G. Interstitial pathomechanisms underlying progressive tubulointerstitial damage. Kidney Blood Press. Res. 22:1999;71-80.
12. Kim Y., Kleppel M., Butoswki R., et al. Differential expression of basement membrane collagen chains in diabetic nephropathy. Am. J. Pathol. 138:1991;413-420.
13. Steffes M.W., Bilous R.W., Sutherland D.E.R., Mauer S.M. Cell and matrix components of the glomerular mesangium in type I diabetes mellitus. Diabetes. 41:1992;679-684.
14. Sharma K., Ziyadeh F. Biochemical events and cytokine interactions linking glucose metabolism to the development of diabetic nephropathy. Sem. Nephrol. 17:1997;80-92.
15. Ziyadeh F.N., Sharma K., Ericksen M., Wolf G. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by activation of transforming growth factor-β J. Clin. Invest. 93:1994;536-542.
16. Hoffman B., Sharma K., Zhu Y., Ziyadeh F.N. Transcriptional activation of transforming growth factor-b1 in mesangial cell culture by high glucose concentration. Kidney Int. 54:1998;1107-1116.
17. Liu Z., Thompson K., Towle H. Carbohydrate regulation of the rat L-type pyruvate kinase gene requires two nuclear factors: LF-A1 and a member of the c-myc family. J. Biol. Chem. 268:1993;12787-12795.
18. Virginie S., Vallet M.C., Henrion A.A., Bucchini D., Raymondjean M., Kahn A., Vaulont S. Differential roles of upstream stimulatory factors 1 and 2 in the transcriptional response of liver genes to glucose. J. Biol. Chem. 273:1998;20175-20179.
19. Sharma K., Ziyadeh F.N. Renal hypertrophy is associated with upregulation of TGF-β1 gene expression in diabetic BB rat and NOD mouse. Am. J. Physiol. 267:1994;F1094-F1101.
20. Sharma K., Guo J., Jin Y., Ziyadeh F.N. Neutralization of TGF-β by anti-TGF-β antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes. 45:1996;522-530.
21. Ziyadeh F., Hoffman B., Guo J., Eltayeb B., Han D., Sharma K. Amelioration of renal insufficiency and excess matrix gene expression by chronic treatment with anti-TGF-b antibody in db/db diabetic mice. J. Am. Soc. Nephr. 9:1998;646A.
22. Park I.-S., Kiyomoto H., Abboud S., Abboud H. Expression of transforming growth factor-b and type IV collagen in early streptozotocin-induced diabetes. Diabetes. 46:1997;473-480.
23. Shankland S.J., Scholey J.W. Expression of transforming growth factor-β1 during diabetic renal hypertrophy. Kidney Int. 46:1994;430-442.
24. Nakamura T., Fukui M., Ebihara I., Osada S., Nagaoka I., Tomino Y., et al. mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes. 42:1993;450-456.
25. Yamamoto T., Noble N., Miller D., Border W. Sustained expression of TGF-beta 1 underlies development of progressive kidney fibrosis. Kidney Int. 45:1994;916-927.
26. Obata J., Nakamura T., Kuroyanagi R., Yoshida Y., Guo D., Inagami T. Candesartan prevents the progression of glomerulosclerosis in genetic hypertensive rats. Kidney Int. 63:1997;S229-S231.
27. Hamaguchi A., Kim S., Ohta K., Yagi K., Yukimura T., Miura K., et al. Transforming growthfactor-beta 1 expression and phenotypic modulation in the kidney of hypertensive rats. Hypertension. 26:1995;199-207.
28. Wu L, Cox A, Roe C, Dziadek M, Cooper M, Gilbert RE. Transforming growth factor beta 1 and renal injury following subtotal nephrectomy in the rat: Role of the renin-angiotensin system. Kidney Int 1997;51:1553-67
29. Kaneto H., Morrissey J., Klanr S. Increased expression of TGF-β1 mRNA in the obstructed kidney rats with unilateral ureteral ligation. Kidney Int. 44:1993;313-321.
30. Iwano M., Atsushi K., Nishino T., Sato H., Nishioka H., Akai Y., et al. Quantification of glomerular TGF-β1 mRNA in patients with diabetes mellitus. Kidney Int. 49:1996;1120-1126.
31. Yamamoto T., Noble N.A., Cohen A.H., Nast C.C., Hishida A., Gold L.I., et al. Expression of transforming growth factor-β isoforms in human glomerular diseases. Kidney Int. 49:1996;461-469.
32. Yamanaka Y., Friess H., Buchler M., Beger H.G., Gold L.I., Korc M. Synthesis and expression of transforming growth factor beta-1, beta-2, and beta-3 in the endocrine and exocrine pancreas. Diabetes. 45:1993;746-756.
33. Sharma K., Ziyadeh F.N., Alzahabi B., McGowan T.A., Kapoor S., Kurnik B.R.C., et al. Increased renal production of transforming growth factor-β 1 in patients with type II diabetes. Diabetes. 46:1997;854-859.
34. Sharma K., Considine R., Michael B., Dunn S., Weisberg L., Kurnik B., et al. Plasma leptin is partly cleared by the kidney and is elevated in hemodialysis patients. Kidney Int. 51:1997;1980-1985.
35. Wolf G., Ziyadeh F. The role of angiotensin II in diabetic nephropathy: Emphasis on nonhemodynamic mechanisms. Amer. J. Kidney Dis. 29:(1):1997;153-163.
36. Campistol J., Inigo P., Jimenez W., Lario S., Clesca P., Oppenheimer F., et al. Losartan decreases plasma levels of TGF-beta 1 in transplant patients with chronic allograft nephropathy. Kidney Int. 56:1999;714-719.
37. Sharma K., Eltayeb B., McGowan T., Dunn S., Alzahabi B., Rohde R., et al. Captopril-induced reduction of serum levels of transforming growth factor-b1 correlates with long-term renoprotection in insulin-dependent diabetic patients. Am. J. Kid. Dis. 34:1999;818-823.
38. Wang L., Zhu Y., Sharma K. Transforming growth factor-b1 stimulates protein kinase A in mesangial cells. J. Biol. Chem. 273:1998;8522-8527.
39. Cai F., Campana W., Tomlinson D.P.F. Transforming growth factor-beta 1 and glial growth factor 2 reduce neurotrophin-3 mRNA expression in cultured Schwann cells via a cAMP-dependent pathway. Mol. Brain Res. 71:1999;256-264.
40. Zhong H., SuYang H., Erdjument-Bromage H., Tempst P., Ghosh S. The transcriptional activity of NF-kB is regulated by the IkB-associated PKAc subunit through a cAMP-independent mechanism. Cell. 89:1997;413-424.
41. Gulati R., Zhu Y., Wang L., Sharma K. Activation of protein kinase A in diabetic rat glomeruli. J. Am. Soc. Nephrol. 9:1998;631A.
42. Hassan M., Minimo C., Zhu Y., Wang L., Buksbaum S., Sharma K. Glomerular hypertrophy is abrogated by anti-TGF-b antibodies in diabetic rats and is associated with CREB-phosphorylation. J. Am. Soc. Nephrol. 10:1999;681A.
43. Hocevar B., Brown T., Howe P. TGF-beta induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway. EMBO J. 18:1999;1345-1356.
44. Chen S., Yuan W., Mori Y., Levenson A., Trojanowska M., Varga J. Stimulation of type I collagen transcription in human skin fibroblasts by TGF-beta: Involvement of Smad 3. J. Invest. Derm. 112:1999;49-57.
45. Nakamura T., Ebihara I., Fukui M., Tomino Y., Koide H. Effect of a specific endothelin receptor A antagonist on mRNA levels for extracellular matrix components and growth factors in diabetic glomeruli. Diabetes. 44:1995;895-899.
46. Ballerman B.J., Skorecki K.L., Brenner B.M. Reduced glomerular angiotensin II receptor density in early untreated diabetes mellitus in the rat. Am. J. Physiol. 247:1984;F110-F116.
47. Schoecklmann H., Rupprecht H., Zauner I., Sterzel R. TGF-beta1-induced cell cycle arrest in renal mesangial cells involves inhibition of cyclin E-cdk 2 activation and retinoblastoma protein phosphorylation. Kidney International. 51:1997;1228-1236.
48. Berridge M.J. Inositol trisphosphate and calcium signalling. Nature. 361:1993;315-325.
49. Joseph S.K. The inositol triphosphate receptor family. Cell Signal. 8:1996;1-7.
50. Monkawa T., Hayashi M., Miyawaki A., Sugiyama T., Yamamoto-Hino M., Hasegawa M., et al. Localization of inositol 1,4,5-trisphosphate receptors in the rat kidney. Kidney Int. 53:1998;296-301.
51. 2+ mobilization. Biochemical and Biophysical Research Communication. 210:1995;378-383.
52. Zhu Z., Tepel M., Neusser M., Zidek W. Transforming growth factor beta 1 modulates angiotensin II-induced calcium influx in vascular smooth muscle. Eur. J. Clin. Invest. 25:1995;317-321.
53. Sharma K., Wang L., Zhu Y., Bokkala S., Joseph S. Transforming growth factor-b1 inhibits type I inositol 1,4,5-trisphosphate receptor expression and enhances its phosphorylation in mesangial cells. J. Biol. Chem. 272:1997;14617-14623.
54. Supattapone S., Danoff S.K., Theibert A., Jospeh S.K., Steiner J., Snyder S.H. Cyclic AMP-dependent phosphorylation of a brain inositol trisphosphate receptor decreases its release of calcium. Proc. Natl. Acad. Sci. USA. 85:1988;8747-8750.
55. Joseph S., Ryan S.V. Phosphorylation of the inositol triphosphate receptor in isolated rat hepatocytes. J. Biol. Chem. 268:1993;23059-23065.
56. Wang L., Hajnoczky G., Sharma K. Transforming growth factor -beta 1down-regulates inositol 1,4,5-trisphosphate receptors in renal arteriolar smooth muscle cells. J. Am. Soc. Nephrol. 9:1998;432A.
57. Sharma K., Wang L., Zhu Y., DeGuzman A., Cao G.-Y., Lynn R., et al. Decreased type I inositol 1,4,5-trisphosphate receptor expression in kidneys from diabetic rodents. Am. J. of Physiol., Renal Fluid and Electrolyte. 276:1999;F54-F61.
58. Hayashi M., Monkawa T., Yoshida T., Sasamura H., Matsumoto M., Inoue T., et al. Intracellular calcium concentration in the inositol trisphoshate receptor type 1 knockout mouse. J. Am. Soc. Nephrol. 10:1999;2094-2101.
59. Bottinger E., Factor V., Tsang M., Weatherbee J., Kopp J., Qian S., et al. The recombinant proregion of transforming growth factor beta1 (latency-associated peptide) inhibits active transforming growth factor beta1 in transgenic mice. Proc. Natl. Acad. Sci. USA. 93:1996;5877-5882.
60. Border W.A., Noble N.A., Yamamoto T., Harper J.R., Yamaguchi Y., Pierschbacher M.D., et al. Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease. Nature. 360:1992;361-364.
61. Ribeiro S., Poczatek M., Schultz-Cherry S., Villain M., Murphy-Ullrich J. The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-B. J. Biol. Chem. 274:(19):1999;13586-13593.
62. Raugi G., Lovett D. Thrombospondin secretion by cultured human glomerular mesangial cells. Am. J. Pathol. 129:1987;364-372.
63. Iyer S.N., Gurujeyalakshmi G., Giri S.N. Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. Journal of Pharmacology & Experimental Therapeutics. 289:(1):1999;211-218.
64. Raghu G., Johnson W.C., Lockhart D., Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. American Journal of Respiratory & Critical Care Medicine. 159:(4 Pt 1):1999;1061-1069.